Enanta Pharma (ENTA) Tops Q4 EPS by 14c

Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of $0.29, $0.14 better than the analyst estimate of $0.15. Revenue for the quarter came in at $14.4 million versus the consensus estimate of $16.44 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Norwegian Cruise Line Holdings (NYSE: NCLH) PT Raised to $20 at UBS
• Bernstein on U.S. telecom: "Another strong quarter"
• iQIYI (IQ) Misses Q2 EPS by 21c